2.52
1.90%
-0.0487
Minerva Neurosciences Inc (NERV) 最新ニュース
What Kind Of Shareholder Appears On The Minerva Neurosciences, Inc.'s (NASDAQ:NERV) Shareholder Register? - Yahoo Lifestyle Australia
Yahoo Lifestyle Australia
Minerva Neurosciences (NASDAQ:NERV) Stock Rating Lowered by StockNews.com - Defense World
Defense World
Is the Options Market Predicting a Spike in Minerva Neurosciences (NERV) Stock? - Yahoo Singapore News
Yahoo Singapore News
Is the Options Market Predicting a Spike in Minerva Neurosciences (NERV) Stock? - Yahoo Singapore News
Yahoo Singapore News
Minerva Neurosciences (NERV) Upgraded to Buy: What Does It Mean for the Stock? - Zacks Investment Research
Zacks Investment Research
Minerva Neurosciences (NERV) Upgraded to Buy: What Does It Mean for the Stock?
Zacks Investment Research
HC Wainwright Brokers Reduce Earnings Estimates for Minerva Neurosciences, Inc. (NASDAQ:NERV) - Defense World
Defense World
Minerva Neurosciences (NERV) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Singapore News
Yahoo Singapore News
Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates - GlobeNewswire
GlobeNewswire
Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates
GlobeNewswire Inc.
Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates - Yahoo Finance
Yahoo Finance
Minerva mauled over roluperidone CRL - The Pharma Letter
The Pharma Letter
Dow Dips Over 100 Points; J.M. Smucker Posts Upbeat Earnings
Benzinga
Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Benzinga
Crude Oil Gains 1%; Macy's Plans To Close 150 Stores
Benzinga
Nasdaq Rises 50 Points; Lowe's Earnings Top Views
Benzinga
Minerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Roluperidone for ... - Yahoo Finance
Yahoo Finance
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business Updates
GlobeNewswire Inc.
Minerva Neurosciences: Q4 Earnings Snapshot - Quartz
Quartz
FDA Action Alert: Alvotech and Minerva - BioSpace
BioSpace
5 FDA Decisions to Watch in Q1 - BioSpace
BioSpace
Minerva Neurosciences | INN - Investing News Network
Investing News Network
Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to Market - Yahoo Finance
Yahoo Finance
Minerva Neurosciences: Up About 250 Percent Since April With An FDA Catalyst Ahead - Seeking Alpha
Seeking Alpha
Minerva Neurosciences Reports 2023 First Quarter Financial Results and Business Updates - Yahoo Finance
Yahoo Finance
Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of ... - GlobeNewswire
GlobeNewswire
Minerva Neurosciences, Inc. (NASDAQ:NERV) Q4 2022 Earnings Call Transcript - Insider Monkey
Insider Monkey
Minerva (NERV) Down; FDA Denies Review Schizophrenia Drug NDA - Yahoo Finance
Yahoo Finance
Minerva Neurosciences Shares Sink On Regulatory Setback For Schizophrenia Candidate - Yahoo Finance
Yahoo Finance
Minerva Neurosciences Inc (NASDAQ: NERV) Submits New Drug Application for Roluperidone In Treating Negative ... - BP Journal
BP Journal
Billionaire Steven Cohen Just Made a Big Bet on Minerva Neurosciences (NERV) Stock - InvestorPlace
InvestorPlace
Minerva Neurosciences Reports Second Quarter 2022 Financial Results and Business Updates - GlobeNewswire
GlobeNewswire
Minerva Neurosciences Announces Study Results Demonstrating Bioequivalence of Phase 2b, Phase 3, and Planned ... - GlobeNewswire
GlobeNewswire
Minerva Neurosciences (NERV) Reports Q2 Loss, Lags Revenue Estimates - Yahoo News UK
Yahoo News UK
Minerva Neurosciences (NERV) Looks Good: Stock Adds 8.4% in Session - Yahoo Singapore News
Yahoo Singapore News
Minerva Neurosciences' roluperidone fails in Phase III study - Clinical Trials Arena
Clinical Trials Arena
Minerva Shares Tank 72% As Schizophrenia Drug Misses Trial Goals - TipRanks.com - TipRanks
TipRanks
EX-99.1 - SEC.gov
SEC.gov
Minerva Neurosciences: NERV Stock Plummets 72% on Schizophrenia Study - InvestorPlace
InvestorPlace
Minerva Neurosciences shares crushed under depression flop, development halted - Fierce Biotech
Fierce Biotech
Moving Average Crossover Alert: Minerva Neurosciences - Yahoo Movies Canada
Yahoo Movies Canada
A Look At The Competitors To Minerva's Roluperidone (NASDAQ:NERV) - Seeking Alpha
Seeking Alpha
Minerva Neurosciences (NERV) Earnings Date and Reports 2024 - MarketBeat
MarketBeat
Minerva Neurosciences (NERV) Stock Forecast and Price Target 2024 - MarketBeat
MarketBeat
NERV Stock Price and Chart — NASDAQ:NERV — TradingView - TradingView
TradingView
Minerva Neurosciences Q1 loss per share $0.30 - Reuters
Reuters
Minerva Neurosciences (NERV) Stock Price, News & Analysis - MarketBeat
MarketBeat
大文字化:
|
ボリューム (24 時間):